ClinicalThought

Share

Program Content

Activities

  • COVID-19 Severity in ICH
    What Is “Severe” COVID-19, and Are the Immunocompromised at Greater Risk?
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2021

    Expires: June 09, 2022

  • COVID-19 Vaccines in ICH
    COVID-19 in Immunocompromised Patients: Vaccine Responsiveness and the Potential for SARS-CoV-2 Variants in Patients With Prolonged Infection
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 28, 2021

    Expires: June 27, 2022

  • Monoclonal Abs for COVID
    New Data on Monoclonal Antibodies for Prevention and Treatment of COVID-19
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 07, 2021

    Expires: July 06, 2022

  • Casirivimab + Imdevimab
    Casirivimab Plus Imdevimab: Monoclonal Antibodies for Treating Hospitalized Patients With COVID-19
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 03, 2021

    Expires: August 02, 2022

  • COVID-19: Racial Disparities
    Race-Related Disparities in Patients With COVID-19
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 04, 2021

    Expires: August 03, 2022

  • TDF and COVID-19
    TDF Exposure and COVID-19 Protection: Association or Causation?
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 16, 2021

    Expires: August 15, 2022

  • COVID-19 Caseload Surge
    Effects of the Surge: COVID-19 Caseload and Mortality Rates
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 03, 2021

    Expires: September 02, 2022

  • Present and Future Treatments
    COVID-19 Treatments: Present and Future
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 21, 2021

    Expires: September 20, 2022

Provided by

ProCE Banner

Supporters

Gilead Sciences, Inc.